title: Cutaneous Sarcoidosis: An Uncommon Side Effect of Pegylated Interferon and Ribavirin Use for Chronic Hepatitis C.
abstract: The treatment of chronic hepatitis C (CHC) has evolved in the past 15 years and combination of pegylated interferon plus ribavirin is its current standard therapy. However, several side effects are commonly observed and frequently lead to transient or definitive interruption of treatment. Although sarcoidosis in its systemic or cutaneous form is a very rare side effect in such circumstances, some cases have been reported even with conventional interferon. This brief review of the literature and description of a case of sarcoidosis occurring in a tattoo and a scar patient's face, during treatment with pegylated interferon alpha-2b plus ribavirin, is an educative report directed in special to dermatologists. The lesion improved after drug interruption and recurred after retreatment with pegylated interferon alpha-2a. We conclude that this side effect must call the attention of doctors to seek for the diagnosis and therapy as soon as possible in such circumstances. No differences were noticed neither with alpha-2a nor alpha-2b pegylated interferon employment.
authors.affiliation: Department of Gastroenterology and Hepatology, Metropolitan University of Santos, Santos, Brazil.
authors.forename: Elson Vidal
authors.initials: EV
authors.lastname: Martins
authors.forename: Ana Karla
authors.initials: AK
authors.lastname: Gaburri
authors.forename: Debora
authors.initials: D
authors.lastname: Gaburri
authors.forename: Angelo
authors.initials: A
authors.lastname: Sementilli